Education
About Us
Working with TipRanks
Follow Us
PTH - ETF AI Analysis
Top Page
Invesco DWA Healthcare Momentum ETF (PTH)
Rating:59Neutral
Price Target:―
Positive Factors
Momentum in Several Top Holdings
Many of the largest positions, such as Revolution Medicines, Guardant Health, and Praxis Precision Medicines, have shown strong recent performance, helping support the ETF’s returns.
Focused Healthcare Exposure
The fund is almost entirely invested in healthcare companies, giving investors targeted access to a sector with long-term growth drivers like aging populations and medical innovation.
Recent Short-Term Performance Upswing
Despite a slightly negative result so far this year, the ETF has shown a strong rebound over the last three months, indicating improving recent momentum.
Negative Factors
High Sector Concentration
With nearly all assets in the healthcare sector, the ETF is heavily exposed to swings in healthcare policy, regulation, and sentiment.
Single-Country Risk
The portfolio is almost entirely invested in U.S. companies, so it offers little geographic diversification if the U.S. market or healthcare industry faces challenges.
Above-Average Expense Ratio
The fund’s expense ratio is relatively high for an ETF, which means more of the returns are eaten up by fees compared with lower-cost alternatives.
PTH vs. SPDR S&P 500 ETF (SPY)
AUM119.87M
RegionNorth America
Expense Ratio0.60%
Beta1.00
IssuerInvesco
Inception DateOct 12, 2006
Dividend Yield3.11%
Asset ClassEquity
Index TrackedDorsey Wright Healthcare Tech Leaders TR
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. Volume7,116
30 Day Avg. Volume13,881
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
70.02Price Target Upside― Downside
Rating ConsensusStrong Buy
Number of Analyst Covering58
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
PTH Summary
PTH is the Invesco DWA Healthcare Momentum ETF, which follows the Dorsey Wright Healthcare Tech Leaders Index. It focuses on U.S. healthcare companies that have been recently strong performers, mainly in areas like biotech, pharmaceuticals, and medical services. Examples of holdings include Tenet Healthcare and Medpace Holdings. Someone might invest in PTH to seek growth from innovative healthcare businesses and to get diversified exposure across many healthcare stocks instead of picking just one. A key risk is that it is heavily concentrated in healthcare, so it can rise or fall sharply with changes in that sector.
How much will it cost me?The Invesco DWA Healthcare Momentum ETF (Ticker: PTH) has an expense ratio of 0.6%, meaning you’ll pay $6 per year for every $1,000 invested. This is higher than average because it’s actively managed, focusing on momentum-driven strategies within the healthcare sector.
What would affect this ETF?The Invesco DWA Healthcare Momentum ETF (PTH) could benefit from ongoing advancements in healthcare technology, an aging population driving demand for medical services, and increased investment in biotechnology and pharmaceuticals. However, it may face challenges from regulatory changes, pricing pressures in the healthcare industry, and potential economic downturns that could reduce consumer spending on healthcare. Its focus on U.S.-based healthcare companies and momentum-driven strategy makes it sensitive to market volatility and sector-specific trends.
PTH Top 10 Holdings
PTH is a pure U.S. healthcare momentum play, and its story is being written mostly by high‑beta biotech names. Praxis Precision Medicines and Roivant Sciences are the current engines, both rising on upbeat trial news and momentum, giving the fund much of its recent spark. On the flip side, Guardant Health and Natera have been lagging, with choppy trading and ongoing profitability worries acting like sand in the gears. Hospital operators like Tenet and HCA are steadier anchors, helping balance the more volatile drug developers at the top.
Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| Roivant Sciences | 5.74% | $6.85M | $20.60B | 170.49% | 58 Neutral | |
| Praxis Precision Medicines | 5.33% | $6.36M | $8.65B | 707.04% | 58 Neutral | |
| Terns Pharmaceuticals | 5.27% | $6.29M | $4.55B | 1126.93% | 45 Neutral | |
| Tenet Healthcare | 3.77% | $4.50M | $20.61B | 85.86% | 74 Outperform | |
| Arrowhead Pharmaceuticals | 3.67% | $4.38M | $8.38B | 252.50% | 57 Neutral | |
| Guardant Health | 3.62% | $4.32M | $11.96B | 131.94% | 61 Neutral | |
| Revolution Medicines | 3.41% | $4.07M | $19.50B | 150.96% | 52 Neutral | |
| HCA Healthcare | 3.16% | $3.77M | $119.15B | 61.38% | 70 Neutral | |
| Natera | 3.09% | $3.69M | $28.08B | 40.86% | 73 Outperform | |
| Celcuity | 3.02% | $3.61M | $5.32B | 980.83% | 44 Neutral |
PTH Technical Analysis
Negative
―
Price Trends
49.26
Negative
48.77
Negative
43.46
Positive
Market Momentum
-0.11
Positive
42.34
Neutral
32.74
Neutral
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For PTH, the sentiment is Negative. The current price of undefined is equal to the 20-day moving average (MA) of 49.04, equal to the 50-day MA of 49.26, and equal to the 200-day MA of 43.46, indicating a neutral trend. The MACD of -0.11 indicates Positive momentum. The RSI at 42.34 is Neutral, neither overbought nor oversold. The STOCH value of 32.74 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for PTH.
PTH Peer Comparison
Comparison Results
Performance Comparison
PTH
Invesco DWA Healthcare Momentum ETF
49.04
11.69
31.30%
FXH
First Trust Health Care AlphaDEX Fund
―
―
―
RSPH
Invesco S&P 500 Equal Weight Health Care ETF
―
―
―
IHF
iShares U.S. Healthcare Providers ETF
―
―
―
PINK
Simplify Health Care ETF
―
―
―
PSCH
Invesco S&P SmallCap Health Care ETF
―
―
―
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents